Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479 · tracked via the Priya Life Science Canada tracker

Sponsor

Sun Pharmaceutical Industries, Inc

Phase

Phase 2/3

Started

2019-04-04

Last updated

2025-10-22

Condition(s) studied

Alopecia Areata

Investigational drug(s) / intervention(s)

CTP-543

CTP-543: Twice daily dosing

Study summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial Exclusion Criteria: * Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis * Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication * Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Primary outcome measure(s)

Number of Participants with Adverse Events as a Measure of Safety — 332 weeks
Effect of CTP-543 on treating hair loss as measured by the Severity of Alopecia Tool (SALT) — 332 weeks

Trial sites (91)

Facility	City	Region
Total Skin and Beauty Dermatology Center	Birmingham	Alabama
Alliance Dermatology & MOHS Center	Phoenix	Arizona
Center for Dermatology and Plastic Surgery/CCT Research	Scottsdale	Arizona
Johnson Dermatology	Fort Smith	Arkansas
Northwest Arkansas Clinical Trials Center, PLLC	Rogers	Arkansas
Kern Research Inc.	Bakersfield	California
Hope Clinical Research	Canoga Park	California
California Dermatology & Clinical Research Institute	Encinitas	California
University of California, Irvine	Irvine	California
Dermatology Research Associates	Los Angeles	California
Quest Dermatology Research	Northridge	California
Kaiser Permanente Northern California - Oakland	Oakland	California
Palmtree Clinical Research, Inc.	Palm Springs	California
Stanford University School of Medicine - Medical Dermatology Clinic	Redwood City	California
Kaiser Permanente South Sacramento	Sacramento	California
Kaiser Permanente Clinical Trials Unit	San Francisco	California
Colorado Center for Dermatology, PLLC d/b/a CODerm Research	Centennial	Colorado
Colorado Medical Research Center	Denver	Colorado
Yale University Church Street Research Unit	New Haven	Connecticut
Skin Care Research, LLC	Boca Raton	Florida
Skin Care Research, LLC	Hollywood	Florida
University of Miami Hospital	Miami	Florida
Floridian Research Institute, LLC	Miami	Florida
Lenus Research & Medical Group, LLC	Sweetwater	Florida
Clinical Research Trials of Florida, Inc.	Tampa	Florida
ForCare Clinical Research	Tampa	Florida
ASR, LLC	Boise	Idaho
Denova Research	Chicago	Illinois
Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana
DS Research	New Albany	Indiana
The Indiana Clinical Trials Center, PC	Plainfield	Indiana
DS Research	Louisville	Kentucky
Qualmedica Research	Owensboro	Kentucky
Massachusetts General Hospital	Boston	Massachusetts
Brigham and Women's Hospital	Boston	Massachusetts
Clarkston Skin Research	Clarkston	Michigan
Clinical Research Institute of Michigan	Clinton Township	Michigan
Minnesota Clinical Study Center	Fridley	Minnesota
University of Minnesota Department of Dermatology	Minneapolis	Minnesota
Vivida Dermatology	Las Vegas	Nevada

+ 51 more sites — see the full list on the official registry below.

More Sun Pharmaceutical Industries, Inc. trials in Canada

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata Recruiting

Other trials for the same condition

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa Recruiting

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata Recruiting

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata Recruiting

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03898479 on ClinicalTrials.gov ↗ ← All trials in Canada